BiotechTube

elafibranor + CHRONO-INDOCID

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 19/100
19
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Drug-drug Interaction

Conditions

Drug-drug Interaction

Trial Timeline

Sep 23, 2019 → Mar 31, 2020

NCT ID
NCT03985969

About elafibranor + CHRONO-INDOCID

elafibranor + CHRONO-INDOCID is a phase 1 stage product being developed by Genfit for Drug-drug Interaction. The current trial status is completed. This product is registered under clinical trial identifier NCT03985969. Target conditions include Drug-drug Interaction.

Hype Score Breakdown

Clinical
6
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03985969Phase 1Completed

Competing Products

15 competing products in Drug-drug Interaction

See all competitors
ProductCompanyStageHype Score
EC905 + verapamilAstellas PharmaPhase 1
29
rosuvastatin + fidaxomicinAstellas PharmaPhase 1
29
enzalutamide + rifampinAstellas PharmaPhase 1
29
ASP3652 + Gemfibrozil + RepaglinideAstellas PharmaPhase 1
29
napabucasin + cytochrome P450 (CYP450) probe drugs or BCRP transporter substrateSumitomo PharmaPhase 1
29
Pyrotinib Maleate + EfavirenzJiangsu Hengrui MedicinePhase 1
25
SHR3680 + digoxin + Rosuvastatin calcium + metformin hydrochlorideJiangsu Hengrui MedicinePhase 1
25
Rifampin + SHR1459Jiangsu Hengrui MedicinePhase 1
29
fostamatinib + Microgynon® 30 (Oral contraceptive) + PlaceboAstraZenecaPhase 1
29
BMS-986020 + Montelukast + Flurbiprofen + DigoxinBristol Myers SquibbPhase 1
29
Simvastatin + VoclosporinAurinia PharmaceuticalsPhase 1
23
Omeprazole 40 MG + Famotidine 40 mg + Telotristat ethyl 250 mgLexicon PharmaceuticalsPhase 1
23
pitavastatin + pitavastatin single dose combined with ceftobiproleBasilea PharmaceuticaPhase 1
23
Raxone (idebenone 150 mg) + Midazolam 2,5 mgSanthera PharmaceuticalsPhase 1
19
Midazolam 5mg Syrup + Vapendavir 264 mg BID + Vapendavir 528 mg QDVaxartPhase 1
19